[go: up one dir, main page]

CY1107555T1 - Μεθοδος για την βιομηχανικη παρασκευη παραγωγων κινολινης - Google Patents

Μεθοδος για την βιομηχανικη παρασκευη παραγωγων κινολινης

Info

Publication number
CY1107555T1
CY1107555T1 CY20071100295T CY071100295T CY1107555T1 CY 1107555 T1 CY1107555 T1 CY 1107555T1 CY 20071100295 T CY20071100295 T CY 20071100295T CY 071100295 T CY071100295 T CY 071100295T CY 1107555 T1 CY1107555 T1 CY 1107555T1
Authority
CY
Cyprus
Prior art keywords
kinolin
producers
industrial production
formula
chaineded
Prior art date
Application number
CY20071100295T
Other languages
English (en)
Inventor
Karl Jansson
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of CY1107555T1 publication Critical patent/CY1107555T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Μέθοδος για την παρασκευή των ενώσεων του γενικού τύπου (I), με αντίδραση παραγώγων εστέρα του κινολινο-3-καρβοξυλικού οξέος του τύπου Α με παράγωγο ανιλίνης του τύπου Β σε έναν διαλύτη που επιλέγεται από ευθείας ή διακλαδισμένης αλύσου αλκάνια και κυκλοαλκάνια ή μίγματα αυτών με σημείο ζέσεως μεταξύ 80 και 200°C.
CY20071100295T 2002-06-12 2007-03-01 Μεθοδος για την βιομηχανικη παρασκευη παραγωγων κινολινης CY1107555T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201778A SE0201778D0 (sv) 2002-06-12 2002-06-12 Process for the manufacture of quinoline derivatives
EP03725956A EP1511732B9 (en) 2002-06-12 2003-05-14 Process for the manufacture of quinoline derivatives

Publications (1)

Publication Number Publication Date
CY1107555T1 true CY1107555T1 (el) 2013-03-13

Family

ID=20288148

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100295T CY1107555T1 (el) 2002-06-12 2007-03-01 Μεθοδος για την βιομηχανικη παρασκευη παραγωγων κινολινης

Country Status (28)

Country Link
EP (1) EP1511732B9 (el)
JP (1) JP4584709B2 (el)
KR (1) KR100979216B1 (el)
CN (1) CN100418950C (el)
AT (1) ATE348814T1 (el)
AU (1) AU2003228195B2 (el)
BR (1) BR0311674A (el)
CA (1) CA2487329C (el)
CY (1) CY1107555T1 (el)
DE (1) DE60310554T2 (el)
DK (1) DK1511732T5 (el)
ES (1) ES2278160T3 (el)
HR (1) HRP20050028B1 (el)
IL (1) IL165155A (el)
IS (1) IS2975B (el)
ME (1) ME00435B (el)
MX (1) MXPA04012276A (el)
NO (1) NO329162B1 (el)
NZ (1) NZ536768A (el)
PL (1) PL210259B1 (el)
PT (1) PT1511732E (el)
RS (1) RS51021B (el)
RU (1) RU2291861C2 (el)
SE (1) SE0201778D0 (el)
SI (1) SI1511732T1 (el)
UA (1) UA78310C2 (el)
WO (1) WO2003106424A1 (el)
ZA (1) ZA200409430B (el)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
CA2625287C (en) 2005-10-19 2016-07-26 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium, and process for the manufacture thereof
EA018031B1 (ru) 2006-06-12 2013-05-30 Тева Фармасьютикал Индастриз, Лтд. Стабильные препараты лаквинимода
ES2375417T3 (es) 2006-11-28 2012-02-29 Valeant Pharmaceuticals International Análogos 1,4-diamino bicíclicos de retigabina como moduladores de los canales de potasio.
PL2682120T3 (pl) 2007-12-20 2017-02-28 Teva Pharmaceutical Industries, Ltd. Stabilne preparaty lakwinimodu
EP2337779B1 (en) 2008-09-03 2017-04-19 Teva Pharmaceutical Industries Ltd. 2-oxo-1,2-dihydro-quinoline modulators of immune function
EP2376456A2 (en) * 2008-12-17 2011-10-19 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
DE102010048788A1 (de) 2009-02-13 2011-05-19 Amw Gmbh Transdermales System mit Immunmodulator
DE102009008851A1 (de) 2009-02-13 2010-08-19 Amw Gmbh Transdermales System mit Immunmodulator
KR20160148050A (ko) 2009-07-30 2016-12-23 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 크론병의 치료
PL3064206T3 (pl) 2009-08-10 2020-02-28 Active Biotech Ab Leczenie choroby Huntingtona z zastosowaniem lakwinimodu
DE102010026879A1 (de) 2010-02-11 2011-08-11 AMW GmbH, 83627 Transdermales System mit Immunmodulator
JP2013521303A (ja) 2010-03-03 2013-06-10 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドを使用したループス腎炎の治療
EA201290860A1 (ru) 2010-03-03 2013-04-30 Тева Фармасьютикал Индастриз Лтд. Лечение ревматоидного артрита комбинацией лаквинимода и метотрексата
KR20130041193A (ko) * 2010-07-09 2013-04-24 테바 파마슈티컬 인더스트리즈 리미티드 5-클로로-4-하이드록시-1-메틸-2-옥소-n-페닐-1,2-다이하이드로퀴놀린-3-카복스아마이드, 염 및 그의 용도
US8871936B2 (en) * 2010-07-09 2014-10-28 Active Biotech Ab Method for manufacturing of quinoline-3-carboxamides
US8580819B2 (en) 2010-07-09 2013-11-12 Teva Pharmaceutical Industries Ltd. Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
EP2537517A1 (en) * 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
CA2851525A1 (en) 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
MX2014009889A (es) 2012-02-16 2014-11-13 Teva Pharma N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos.
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
CN103626701A (zh) * 2012-08-28 2014-03-12 天津药物研究院 一种制备喹啉衍生物的方法
CN103626702A (zh) * 2012-08-30 2014-03-12 天津药物研究院 一种制备喹啉酮衍生物的方法
CN104955522A (zh) 2012-11-07 2015-09-30 梯瓦制药工业有限公司 拉喹莫德胺盐
WO2014153145A2 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
AU2015253330A1 (en) 2014-04-29 2016-12-01 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status
ES2631194T3 (es) 2014-09-23 2017-08-29 Active Biotech Ab Quinolincarboxamidas para usar en el tratamiento del mieloma múltiple
WO2016078921A1 (en) 2014-11-19 2016-05-26 Active Biotech Ab Quinoline carboxamides for use in the treatment of leukemia
US20230085883A1 (en) 2020-03-03 2023-03-23 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
CN111732540B (zh) * 2020-07-20 2020-11-13 湖南速博生物技术有限公司 一种罗喹美克的制备方法
AU2021313388A1 (en) 2020-07-23 2023-01-19 Erasmus University Medical Center Rotterdam (Erasmus Mc) S100 proteins as novel therapeutic targets in myeloproliferative neoplasms
US20240091215A1 (en) 2021-01-18 2024-03-21 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
EP4346773A1 (en) 2021-05-25 2024-04-10 Active Biotech AB A plurality of tasquinimod particles and use thereof
JP2024524158A (ja) 2021-07-02 2024-07-05 アクティブ バイオテック エイビー タスキニモドを含有する医薬製品および前記製品の純度を評価する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US6077851A (en) * 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives

Also Published As

Publication number Publication date
DE60310554D1 (de) 2007-02-01
BR0311674A (pt) 2008-01-08
ZA200409430B (en) 2006-02-22
ATE348814T1 (de) 2007-01-15
PL210259B1 (pl) 2011-12-30
RU2291861C2 (ru) 2007-01-20
ES2278160T3 (es) 2007-08-01
HRP20050028A2 (en) 2006-02-28
SE0201778D0 (sv) 2002-06-12
CA2487329A1 (en) 2003-12-24
AU2003228195A1 (en) 2003-12-31
NZ536768A (en) 2006-10-27
EP1511732B1 (en) 2006-12-20
RU2005100054A (ru) 2005-07-10
PL373817A1 (en) 2005-09-19
JP2005535612A (ja) 2005-11-24
IS2975B (is) 2017-07-15
ME00435B (me) 2011-10-10
DK1511732T5 (da) 2007-10-01
WO2003106424A1 (en) 2003-12-24
DE60310554T2 (de) 2007-11-29
IL165155A0 (en) 2005-12-18
RS51021B (sr) 2010-10-31
IL165155A (en) 2009-11-18
KR100979216B1 (ko) 2010-08-31
NO20045703L (no) 2004-12-29
IS7550A (is) 2004-11-24
DK1511732T3 (da) 2007-04-30
NO329162B1 (no) 2010-08-30
JP4584709B2 (ja) 2010-11-24
CA2487329C (en) 2010-11-16
CN100418950C (zh) 2008-09-17
CN1659146A (zh) 2005-08-24
AU2003228195B2 (en) 2009-05-28
EP1511732A1 (en) 2005-03-09
HRP20050028B1 (hr) 2013-07-31
KR20050016537A (ko) 2005-02-21
PT1511732E (pt) 2007-03-30
SI1511732T1 (sl) 2007-06-30
RS107604A (en) 2007-02-05
MXPA04012276A (es) 2005-04-08
EP1511732B9 (en) 2008-11-12
UA78310C2 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
CY1107555T1 (el) Μεθοδος για την βιομηχανικη παρασκευη παραγωγων κινολινης
HRP20040690B1 (en) Novel fluorene carboxylic acid esters, methods for the production thereof, and use of the same as pharmaceuticals
BRPI0408160B1 (pt) Processo para o preparo de ésteres do ácido nicotínico substituído e intermediários de enamina para uso nesse processo
NO20032731L (no) Fremgangsmåte for fremstilling av sulfonamid-substituerte imidazotriazinoner
DE60335865D1 (de) Verfahren zur herstellung von cilostazol
DK1347965T3 (da) Hidtil ukendte desloratidinsalte, fremgangsmåde til syntese deraf samt farmaceutiske præparater deraf
EE04593B1 (et) Alendroonhappe valmistamismeetod
EA200500688A1 (ru) Новый способ получения синтетических промежуточных соединений для пестицидов
EE05136B1 (et) Asendatud imidasopridiinhendite valmistamise meetod
HUP0200058A2 (hu) Eljárás N-(4-trifluor-metil-fenil)-5-metil-izoxazol-4-karboxamid kristályosítására
NO20055924L (no) Metode for fremstilling av (2s)-3-(4- {2-[Amino]-2-Oksoetoksy}Fenyl)-2-Etoksypropansyrederivater
WO2004091549A3 (en) Process for making alpha-substituted hydroxamic acids
TW200505911A (en) Crystal of benzimidazole derivative and process for producing the same
NO20054875L (no) Syntese av 2-klormetyl-6-metylbenzosyreestere
DE60128336D1 (de) Eine zwischenverbindung und verfahren zu deren herstellung
SE0201005D0 (sv) New Process
ATE414704T1 (de) Verfahren zur synthese von pergolid
DK1163257T3 (da) Fremgangsmåde til fremstilling af 4,4-dimethyl-3beta-hydroxypregna-8,14-dien-21-carboxylsyreestere og mellemprodukter i fremgangsmåden
TW200712247A (en) Method of processing ferric compound by plasma technique and preparing ferric oxide
HUP0202296A2 (hu) Eljárás szubsztituált benzizotiazolszármazékok előállítására